Bicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report)'s stock price hit a new 52-week low during mid-day trading on Friday . The company traded as low as $12.17 and last traded at $12.21, with a volume of 152520 shares changing hands. The stock had previously closed at $12.61.
Analyst Ratings Changes
BCYC has been the subject of several analyst reports. B. Riley reduced their price objective on shares of Bicycle Therapeutics from $28.00 to $17.00 and set a "neutral" rating for the company in a research note on Friday, December 13th. HC Wainwright reaffirmed a "buy" rating and issued a $33.00 price objective on shares of Bicycle Therapeutics in a research note on Monday, January 13th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $35.00 price objective on shares of Bicycle Therapeutics in a research note on Friday, November 1st. Stephens reaffirmed an "equal weight" rating and issued a $15.00 price objective on shares of Bicycle Therapeutics in a research note on Wednesday, January 22nd. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $32.00 price objective on shares of Bicycle Therapeutics in a research note on Monday, January 13th. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat, Bicycle Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $33.25.
Get Our Latest Stock Report on Bicycle Therapeutics
Bicycle Therapeutics Trading Down 1.7 %
The stock has a market cap of $803.74 million, a P/E ratio of -3.54 and a beta of 0.93. The firm's fifty day moving average is $14.74 and its 200 day moving average is $20.34.
Insider Transactions at Bicycle Therapeutics
In other news, insider Santiago Arroyo sold 4,943 shares of the business's stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $14.09, for a total transaction of $69,646.87. Following the transaction, the insider now owns 69,057 shares in the company, valued at approximately $973,013.13. The trade was a 6.68 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO Alistair Milnes sold 4,578 shares of the business's stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $14.09, for a total transaction of $64,504.02. Following the transaction, the chief operating officer now owns 100,724 shares in the company, valued at approximately $1,419,201.16. The trade was a 4.35 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 27,677 shares of company stock worth $392,413. 8.50% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the stock. Assetmark Inc. bought a new stake in Bicycle Therapeutics in the third quarter valued at about $34,000. GAMMA Investing LLC increased its stake in Bicycle Therapeutics by 105.1% in the third quarter. GAMMA Investing LLC now owns 2,026 shares of the company's stock valued at $46,000 after acquiring an additional 1,038 shares during the period. Avior Wealth Management LLC bought a new stake in Bicycle Therapeutics in the fourth quarter valued at about $57,000. China Universal Asset Management Co. Ltd. increased its stake in Bicycle Therapeutics by 69.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 7,138 shares of the company's stock valued at $162,000 after acquiring an additional 2,918 shares during the period. Finally, JPMorgan Chase & Co. increased its stake in Bicycle Therapeutics by 26.8% in the third quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company's stock valued at $191,000 after acquiring an additional 1,782 shares during the period. Institutional investors own 86.15% of the company's stock.
About Bicycle Therapeutics
(
Get Free Report)
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.
Recommended Stories
Before you consider Bicycle Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicycle Therapeutics wasn't on the list.
While Bicycle Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
